Feb 7 (Reuters) - AbbVie ( ABBV ) said that the U.S. Food and Drug Administration

approved its drug for complicated intra-abdominal infections on Friday.

AbbVie ( ABBV ) and co-developer Pfizer's ( PFE ) drug, Emblaveo, is approved in combination with an

antibiotic medication for patients 18 years and older with such infections.

Intra-abdominal infections (IAIs) are a group of infections that occur in the abdominal

cavity. They can range from uncomplicated appendicitis to more serious conditions where the

infection spreads from the pancreas.

AbbVie ( ABBV ) said the drug will be available for commercial use in the U.S. in the third quarter

of 2025.

AbbVie ( ABBV ) holds the rights to commercialize the therapy in the U.S. and Canada, with Pfizer ( PFE )

responsible for its commercialization in all other areas.